Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down - Time to Sell?

Key Points

• Iovance shares gapped down, opening at $3.51 after closing at $4.09 and last trading around $3.64 on heavy volume (~14.8M shares), reflecting a sharp near-term selloff.
• Analysts are mixed with a MarketBeat consensus rating of "Hold" and a consensus target of $8.88, while individual price targets and ratings range widely (e.g., Goldman $2 sell vs. Barclays $11 overweight).
• The company reported quarterly EPS of -$0.19 (in line with estimates) and revenue of $71.4M (below the $77.8M estimate) while revenue rose 44.9% year‑over‑year and the business remains unprofitable with negative margins.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report)'s stock price gapped down prior to trading on Thursday . The stock had previously closed at $4.09, but opened at $3.51. Iovance Biotherapeutics shares last traded at $3.6430, with a volume of 14,841,725 shares trading hands.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Citizens Jmp upgraded Iovance Biotherapeutics from a "market perform" rating to a "market outperform" rating and set a $5.00 price target on the stock in a report on Tuesday, March 3rd. Wall Street Zen upgraded Iovance Biotherapeutics from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. Barclays increased their price target on Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an "overweight" rating in a report on Wednesday, February 25th. The Goldman Sachs Group reiterated a "sell" rating and issued a $2.00 price target on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. Finally, UBS Group increased their price target on Iovance Biotherapeutics from $2.00 to $4.00 and gave the stock a "neutral" rating in a report on Thursday, March 5th. Six equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Iovance Biotherapeutics presently has a consensus rating of "Hold" and a consensus target price of $8.88.

Iovance Biotherapeutics Price Performance

The firm has a fifty day moving average price of $3.81 and a two-hundred day moving average price of $2.93. The stock has a market capitalization of $1.58 billion, a PE ratio of -3.16 and a beta of 0.69.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.19) EPS for the quarter, hitting the consensus estimate of ($0.19). The company had revenue of $71.43 million for the quarter, compared to the consensus estimate of $77.84 million. Iovance Biotherapeutics had a negative return on equity of 54.54% and a negative net margin of 148.41%.Iovance Biotherapeutics's quarterly revenue was up 44.9% on a year-over-year basis. During the same period last year, the business posted ($0.36) EPS. On average, research analysts expect that Iovance Biotherapeutics, Inc. will post -0.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IOVA. Invenomic Capital Management LP raised its stake in Iovance Biotherapeutics by 27.1% in the third quarter. Invenomic Capital Management LP now owns 10,541,608 shares of the biotechnology company's stock worth $22,875,000 after buying an additional 2,246,945 shares in the last quarter. Mirador Capital Partners LP lifted its holdings in Iovance Biotherapeutics by 100.9% during the fourth quarter. Mirador Capital Partners LP now owns 1,034,544 shares of the biotechnology company's stock worth $2,824,000 after buying an additional 519,519 shares during the period. Aberdeen Group plc boosted its position in Iovance Biotherapeutics by 25.1% during the 4th quarter. Aberdeen Group plc now owns 759,522 shares of the biotechnology company's stock valued at $2,073,000 after acquiring an additional 152,312 shares in the last quarter. Rhenman & Partners Asset Management AB boosted its position in Iovance Biotherapeutics by 69.5% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 1,097,827 shares of the biotechnology company's stock valued at $2,382,000 after acquiring an additional 450,000 shares in the last quarter. Finally, Rafferty Asset Management LLC increased its holdings in shares of Iovance Biotherapeutics by 65.1% in the 3rd quarter. Rafferty Asset Management LLC now owns 482,975 shares of the biotechnology company's stock valued at $1,048,000 after acquiring an additional 190,522 shares during the period. 77.03% of the stock is currently owned by institutional investors.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company's lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance's pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance's TIL platform harnesses a patient's own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.